Gilead Sciences, Inc.
GILD
NASDAQ62.45
Gilead Sciences, Inc.
NASDAQ:GILD
RECENT
PRICE
62.45
P/E
RATIO
19.06
(PEG:0.00)
P/E RATIO
RELATIVE
TO S&P
0.95
DIV
YLD
3.39%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
- - Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 09/22:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
1.65
(0.65)
0.61
- -
2.28
0.87
0.91
- -
2.90
1.09
1.13
- -
3.88
1.46
1.58
- -
4.64
1.69
1.62
- -
5.41
1.81
2.26
- -
6.41
1.71
1.85
- -
7.33
2.01
1.91
- -
16.35
7.95
8.06
- -
22.29
12.37
13.38
1.28
22.70
10.08
11.89
1.83
19.97
3.54
8.65
2.09
17.05
4.20
5.76
2.29
17.68
4.24
6.55
2.54
19.64
0.10
5.98
2.74
21.74
4.96
8.60
2.87
21.91
3.29
6.34
2.18
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.06
0.99
0.04
1.86
0.06
2.26
0.13
3.52
0.04
3.42
0.09
4.35
0.26
6.15
0.12
7.44
0.37
10.14
0.51
12.66
0.56
14.11
0.45
15.64
0.71
16.48
0.65
17.74
0.52
14.48
0.46
16.77
0.43
12.44
CAPEX per share
Book Value per share
1,836
1,858
1,841
1,809
1,712
1,550
1,515
1,529
1,522
1,464
1,339
1,307
1,298
1,270
1,257
1,256
1,256
Comm.Shares outs.(m)
(23.8)
(1.3)
- -
22.8
1.3
- -
22.4
1.0
- -
15.8
0.2
- -
11.6
0.6
- -
11.0
0.7
- -
16.5
1.1
- -
27.7
1.6
- -
11.2
0.6
- -
8.5
0.4
1.2%
8.3
0.4
2.2%
20.5
0.9
2.9%
17.5
0.7
3.1%
15.4
0.6
3.9%
706.3
18.7
4.0%
13.6
0.5
4.3%
19.1
1.0
3.4%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (30/6/22 | Q2)
Total liabilities
- -
Total assets
$62,870 m.
Long-term debt
- -
Cash and equiv.
- -
Goodwill $8,314 m.
Retained earnings $16,130 m.
Common stock 1,256 m. shares
Market Capitalisation
$78,135 m. (as of 27/9/22)
8,385
45.2%
9,703
41.3%
11,202
40.4%
24,890
61.3%
32,639
68.0%
30,390
58.0%
26,107
54.1%
22,127
37.1%
22,449
19.1%
24,689
16.5%
27,305
36.3%
27,515
25.0%
Revenue (m)
Operating margin
302
2,804
278
2,592
345
3,075
1,050
12,101
1,098
18,108
1,158
13,501
1,286
4,628
1,429
5,455
1,404
5,386
1,480
123
2,050
6,225
1,583
4,137
Depreciation (m)
Net profit (m)
23.6%
33.4%
28.7%
26.7%
27.3%
27.4%
18.8%
48.6%
16.4%
55.5%
21.1%
44.4%
65.7%
17.7%
30.0%
24.7%
(4.0)%
24.0%
94.7%
0.5%
25.1%
22.8%
51.9%
14.7%
Income tax rate
Net profit margin
11,404
7,606
6,739
1,886
7,055
9,310
948
3,939
11,369
11,953
11,921
15,426
14,872
21,195
18,534
11,226
26,346
18,887
20,188
30,795
20,442
25,231
24,574
21,387
20,537
22,094
22,525
4,599
28,645
18,202
3,162
25,179
21,069
13,705
- -
- -
Working capital (m)
Long-term debt (m)
Equity (m)
20.2%
22.5%
41.6%
17.0%
19.0%
27.8%
20.8%
20.5%
27.0%
43.6%
44.7%
78.4%
45.2%
43.6%
97.7%
30.2%
32.0%
71.5%
8.6%
20.8%
22.6%
11.7%
14.0%
25.5%
12.4%
10.0%
23.9%
0.3%
3.9%
0.7%
12.4%
13.7%
29.5%
5.2%
10.8%
Infinity%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
24,352
18,718
18,059
Receivables
3,582
4,892
4,493
Inventory
922
1,683
1,618
Other
1,440
2,013
2,141
Current assets
30,296
15,996
14,772
Acc. Payable
713
844
705
Debt due
2,499
2,757
1,516
Other
6,547
7,796
9,389
Current liab.
9,759
11,397
11,610
100.0%
61.9%
100.0%
7.2%
100.0%
9.2%
100.0%
40.9%
89.7%
59.0%
81.8%
83.2%
41.0%
30.5%
45.5%
74.7%
40.2%
57.2%
(2,704.1)%
63.5%
42.1%
36.9%
8.1%
39.2%
Plowback ratio
Div.&Repurch. to FCF
Gilead Sciences, Inc. (US) started trading on January 3, 1992 (cik: 0000882095), operates in the Healthcare sector (Drug Manufacturers—General industry), has 14,400 full-time employees, and is led by Mr. Daniel O'Day. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
1.70%
17.18%
Cash flow
2.87%
38.71%
Earnings
1219.97%
572.28%
Dividends
7.20%
- -
Book value
1.63%
10.51%
Insider trading
Type
Shares
Date
Dickinson Andrew D
Exempt
1,027
09/10/22
Dickinson Andrew D
InKind
476
09/10/22
Dickinson Andrew D
Exempt
1,027
09/10/22
Mercier Johanna
Exempt
990
09/10/22
Mercier Johanna
InKind
458
09/10/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
5,548
5,143
6,577
7,421
24,689
2021
6,423
6,217
7,421
7,244
27,305
2022
6,590
6,260
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
1.23
(2.66)
0.29
1.23
0.10
2021
1.38
1.21
2.06
0.30
4.96
2022
0.02
0.91
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
0.70
0.68
0.68
0.68
2.74
2021
0.73
0.71
0.72
0.71
2.87
2022
0.75
- -
- -
- -
- -
03/30/2022
Justice Department Probes Alleged Sales of Counterfeit HIV Drugs
The Wall Street Journal - Read more...
02/01/2022
Gilead’s Revenue Declines on Waning Sales of Covid-19 Drug
The Wall Street Journal - Read more...
01/18/2022
Gilead Alleges Counterfeiting Ring Sold Its HIV Drugs
The Wall Street Journal - Read more...
12/22/2021
Gilead’s Remdesivir Covid-19 Therapy Cuts Risk of Hospitalization in Study
The Wall Street Journal - Read more...
07/30/2021
Amazon, Pinterest, Robinhood, Chevron: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
07/29/2021
Robinhood, Didi Global, Facebook, Credit Suisse: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
06/23/2021
Illicit Covid-19 Drugs Bound for Mexico Seized by U.S. Authorities
The Wall Street Journal - Read more...
04/30/2021
Twitter, Amazon, Clorox, Chevron: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
04/29/2021
Facebook, Twitter, eBay, Apple: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
03/15/2021
Gilead and Merck Join Forces to Develop Long-Acting HIV Treatment
The Wall Street Journal - Read more...
02/05/2021
Pinterest, Activision Blizzard, Peloton: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
02/04/2021
PayPal, eBay, Qualcomm: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
01/11/2021
Eli Lilly, Twitter, NIO: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
12/10/2020
Gilead to Pay $1.4 Billion for Hepatitis Drugmaker MYR GmbH
The Wall Street Journal - Read more...
11/20/2020
Pfizer, Gilead, Ross: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
11/20/2020
WHO Recommends Against Use of Gilead Covid-19 Drug Remdesivir
The Wall Street Journal - Read more...
10/28/2020
Gilead Quarterly Revenue Rises on Remdesivir Sales
The Wall Street Journal - Read more...
10/01/2020
All Remdesivir Supplies to Be Distributed in U.S. by Maker Gilead
The Wall Street Journal - Read more...